Listen to part IIII of our #ACR20 Day 3 recap. Follow the link below or find us on Apple podcasts. https://t.co/cI9UGyFwIJ https://t.co/NiTeNxsGaD

• https://bit.ly/32ujFPP

We as young physicians should start paying attention to our contracts-🤦‍♀️ takeaways 1-know your worth (see MGMA compensation yearly) 2-malpractive/ tail coverage 3-non-compete 4-termination clause 5-gurantee @RheumNow #ACR20 #5M036

RheumNow’s expanded coverage of the #ACR20 annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.

Gender disparity in Ankylosing Spondylitis symptoms. 1⃣Women ⬆️Achilles tendonitis, plantar fasciitis, joint swelling, BASDAI>40, DMARD use 2⃣HLA-B not associated w/ enthesitis @RheumNow #ACR20 Abs#1872 https://t.co/bxiNUjY1Xh

NEW ACR2020 Draft Guidelines for the Pharmacologic Treatment of RA All the guidelines in 2 tables! 1. MTX 1st, oral > SC 2. Minimize GC! 3. TTT TTT TTT 4. Biologic/tsDMARD > Triple Tx 5. Taper MTX 1st Close to my practice; suspect will be controversial! #ACR20 #ACRambassador https://t.co/iFSlq1H65V

Following RITAZAREM, would you use rituximab maintenance for ANCA-associated vasculitis patients (cost aside)? @RheumNow

IN GOUT: CARES study said febuxostat increases CV risk; Todays FAST study says No incr CV risk w/ FEB. In your Gout pt w/ CV hx, would you use febuxostat? #ACR2020

Following the results of the FAST trial, would you have any concerns about prescribing febuxostat if clinically indicated? #ACR20 @RheumNow

Just as a reminder of how we felt back then. https://t.co/onIMqa5DAp Also note, the hypogammaglob gap has widened a little (then 25 v 21, now 36 v 26). Now we have the extended follow-up data, where no additional benefit was noted, do we still feel that excited? #ACR20 @RheumNow

• https://twitter.com/drdavidliew/status/1193573759749365760?s=20

Improvement of enthesitis US scores consistent with bDMARD initiation/change 1⃣MASEI and OMERACT scores improved at 3 mo/6mo 2⃣Associated with clinical activity outcomes @RheumNow #ACR20 Abs#1552 https://t.co/qnSEBaXrJo

RITZAREM (RTX vs AZA maintenance post RTX induction relapsing AAV) what happened post-study? After #ACR19, hope RTX confers ongoing benefit Answer: no. Same decline Is 1g q4m dosing not justified? Does that mean RTX needs to be continued, and in whom? #ACR20 ABST2052 @RheumNow https://t.co/tldGqca8xC

Did you have diversity and inclusion and/or bias training during fellowship? #ACR20 @RheumNow

GOUT: CARES study says febuxostat has high CV risk, new FAST study says no incr risk. Would you give FEB to a gout pt w/ CV risk?